Human Mast Cell Line (LAD2)

This novel mast cell line (LAD2) is derived from CD34+ cells obtained via marrow aspiration from a patient with aggressive mastocytosis, where no KIT mutations were identified. The cells are characterized by their slow proliferation, dependency on stem cell factor (SCF) for growth, and expression of functional surface FcεRI receptors, which are crucial for studying mast cell biology. LAD2 cells closely resemble primary human mast cells in terms of growth characteristics, receptor expression, and functional responses, making them a valuable model for investigating allergic reactions, mast cell activation, and degranulation processes. Specifically, LAD2 has functional FcεRI and FcyRI receptors and expresses CD4, 9, 13, 22, 45, 64, 71, 103, 117, 132, CCR5 and CXCR4, as well as CD14, 31 and 32, to a lesser degree. Cells are susceptible to T-tropic, M-tropic, and dual tropic HIV infection. LAD2 cells are widely used in research focused on allergy, immunology, and mast cell-related diseases. Their ability to degranulate in response to immunologic stimuli and their stable phenotype provide a reliable platform for testing the effects of various allergens, drugs, and therapeutic interventions. Additionally, LAD2 cells have been instrumental in studying the molecular mechanisms underlying mast cell activation and signaling pathways.Compared to LADR cells, LAD2 cells proliferate faster and are less granulated. LAD2 cells express a slightly different profile of surface markers and have lower tryptase expression compared to LADR cells, which influences their utility in specific research contexts.Note: understanding the recommended culture conditions and expected behaviour of this cell line are critical for establishing successful cultures. Additional cell lines of interest:Cat. T8156 - Human Mast Cell Line (LADR)

Male, 44, Mastocytosis

PriCoat™ T25 Flasks (G299) are recommended for optimal cell culture. PriGrow X Series Medium for T8157 (TM8157) + 100ng/ml human Stem Cell Factor (Z100815) + 2mM L-Glutamine (G275) + 1% Penicillin/Streptomycin Solution (G255), 37.0°C, 5% CO2. Replace half of the medium with an equal volume of fresh medium, weekly. Do not allow cells to become over-confluent or grow past a density of 1x106 cells/ml. Note: it is normal to observe cell death in the first two weeks after thawing. Allow cells to recover under the recommended culture conditons. Cells are slow-growing and extremely sensitive to mycoplasma contamination; routine testing should be performed. *Cells may lose functionality as a result of continuous culture. Degranulation assays must be conducted every 2 months to test functionality -protocol can be found under the "Documents" tab. 

Suspension; Rounded, granulated; some large aggregates at higher densities

FcεRI, CD33, CD34, CD63, CD117, CD133, CD193

Initially grow slowly; double in 2-4 weeks under optimal conditions.

500,000-800,000

Bone Marrow